Medartis Holding AG
SIX:MED

Watchlist Manager
Medartis Holding AG Logo
Medartis Holding AG
SIX:MED
Watchlist
Price: 52 CHF -3.88% Market Closed
Market Cap: 706.2m CHF
Have any thoughts about
Medartis Holding AG?
Write Note

Intrinsic Value

The intrinsic value of one MED stock under the Base Case scenario is 87.83 CHF. Compared to the current market price of 52 CHF, Medartis Holding AG is Undervalued by 41%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MED Intrinsic Value
87.83 CHF
Undervaluation 41%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Medartis Holding AG

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for MED cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about MED?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Health Care Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Medartis Holding AG

Provide an overview of the primary business activities
of Medartis Holding AG.

What unique competitive advantages
does Medartis Holding AG hold over its rivals?

What risks and challenges
does Medartis Holding AG face in the near future?

Summarize the latest earnings call
of Medartis Holding AG.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Medartis Holding AG.

Provide P/S
for Medartis Holding AG.

Provide P/E
for Medartis Holding AG.

Provide P/OCF
for Medartis Holding AG.

Provide P/FCFE
for Medartis Holding AG.

Provide P/B
for Medartis Holding AG.

Provide EV/S
for Medartis Holding AG.

Provide EV/GP
for Medartis Holding AG.

Provide EV/EBITDA
for Medartis Holding AG.

Provide EV/EBIT
for Medartis Holding AG.

Provide EV/OCF
for Medartis Holding AG.

Provide EV/FCFF
for Medartis Holding AG.

Provide EV/IC
for Medartis Holding AG.

Show me price targets
for Medartis Holding AG made by professional analysts.

What are the Revenue projections
for Medartis Holding AG?

How accurate were the past Revenue estimates
for Medartis Holding AG?

What are the Net Income projections
for Medartis Holding AG?

How accurate were the past Net Income estimates
for Medartis Holding AG?

What are the EPS projections
for Medartis Holding AG?

How accurate were the past EPS estimates
for Medartis Holding AG?

What are the EBIT projections
for Medartis Holding AG?

How accurate were the past EBIT estimates
for Medartis Holding AG?

Compare the revenue forecasts
for Medartis Holding AG with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Medartis Holding AG and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Medartis Holding AG against its competitors.

Analyze the profit margins
(gross, operating, and net) of Medartis Holding AG compared to its peers.

Compare the P/E ratios
of Medartis Holding AG against its peers.

Discuss the investment returns and shareholder value creation
comparing Medartis Holding AG with its peers.

Analyze the financial leverage
of Medartis Holding AG compared to its main competitors.

Show all profitability ratios
for Medartis Holding AG.

Provide ROE
for Medartis Holding AG.

Provide ROA
for Medartis Holding AG.

Provide ROIC
for Medartis Holding AG.

Provide ROCE
for Medartis Holding AG.

Provide Gross Margin
for Medartis Holding AG.

Provide Operating Margin
for Medartis Holding AG.

Provide Net Margin
for Medartis Holding AG.

Provide FCF Margin
for Medartis Holding AG.

Show all solvency ratios
for Medartis Holding AG.

Provide D/E Ratio
for Medartis Holding AG.

Provide D/A Ratio
for Medartis Holding AG.

Provide Interest Coverage Ratio
for Medartis Holding AG.

Provide Altman Z-Score Ratio
for Medartis Holding AG.

Provide Quick Ratio
for Medartis Holding AG.

Provide Current Ratio
for Medartis Holding AG.

Provide Cash Ratio
for Medartis Holding AG.

What is the historical Revenue growth
over the last 5 years for Medartis Holding AG?

What is the historical Net Income growth
over the last 5 years for Medartis Holding AG?

What is the current Free Cash Flow
of Medartis Holding AG?

Discuss the annual earnings per share (EPS)
trend over the past five years for Medartis Holding AG.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Medartis Holding AG

Current Assets 258.1m
Cash & Short-Term Investments 127.1m
Receivables 50m
Other Current Assets 81m
Non-Current Assets 206.4m
Long-Term Investments 35.2m
PP&E 79.7m
Intangibles 60.1m
Other Non-Current Assets 31.3m
Current Liabilities 57.1m
Accounts Payable 7.5m
Accrued Liabilities 6.5m
Other Current Liabilities 43.1m
Non-Current Liabilities 134.8m
Long-Term Debt 114.7m
Other Non-Current Liabilities 20.1m
Efficiency

Earnings Waterfall
Medartis Holding AG

Revenue
220.3m CHF
Cost of Revenue
-42.9m CHF
Gross Profit
177.4m CHF
Operating Expenses
-167.8m CHF
Operating Income
9.6m CHF
Other Expenses
-5.6m CHF
Net Income
4m CHF

Free Cash Flow Analysis
Medartis Holding AG

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In the first half of the year, a series of mix effects triggered a gross margin decline by approximately 250 basis points. These effects included manufacturing sales dilution, distributor sales depressions, and inventory efficiency initiatives reducing production utilization. Nevertheless, the company sees these impacts diminishing in the second half. Operating expenses (OpEx) decreased around 7 percentage points year-on-year, indicating strong business leverage and confidence in meeting the full-year EBITDA margin guidance. Despite a CHF 50 million cash outflow and increased investments, the management expects H2 cash outflow to be significantly lower due to working capital improvements, non-recurrence of certain investments, and anticipated higher sales and gross margins. Consolidating the U.S. office to Warsaw improved the cost basis, with potential for expanding in various medical indications. The company confirms guidance for the full year, with internal sales growth between 15-18% and an EBITDA margin of 13-15%.

What is Earnings Call?
Fundamental Scores

MED Profitability Score
Profitability Due Diligence

Medartis Holding AG's profitability score is 48/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
Positive 1-Year Revenue Growth
48/100
Profitability
Score

Medartis Holding AG's profitability score is 48/100. The higher the profitability score, the more profitable the company is.

MED Solvency Score
Solvency Due Diligence

Medartis Holding AG's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Low D/E
Long-Term Solvency
74/100
Solvency
Score

Medartis Holding AG's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MED Price Targets Summary
Medartis Holding AG

Wall Street analysts forecast MED stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MED is 104.52 CHF with a low forecast of 93.32 CHF and a high forecast of 115.5 CHF.

Lowest
Price Target
93.32 CHF
79% Upside
Average
Price Target
104.52 CHF
101% Upside
Highest
Price Target
115.5 CHF
122% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for MED?

Click here to dive deeper.

Dividends

Medartis Holding AG
does not pay dividends
Shareholder Yield

Current shareholder yield for MED is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Medartis Holding AG Logo
Medartis Holding AG

Country

Switzerland

Industry

Health Care

Market Cap

706.2m CHF

Dividend Yield

0%

Description

Medartis Holding AG operates as a medical device company. The company is headquartered in Basel, Basel-Stadt and currently employs 684 full-time employees. The company went IPO on 2018-03-23. The Group develops, manufactures and distributes to surgeons, hospitals and medical centers titanium screws, plates, surgical instruments and system solutions for internal fracture fixation. Medartis AG, the Company's wholly-owned subsidiary, has developed such technologies as TriLock for locking the screw into the plate, SpeedTip, a screw that does not require pre-drilling, and HexaDrive self-holding screw and screw-driver. The company has two product lines. The APTUS product line comprises upper and lower extremities products for hand, wrist, elbow, shoulder and foot fixation. The MODUS line combines products dedicated to cranio-maxillofacial (CMF) surgery. The Group's products are sold globally in more than 30 countries, including Germany and the United States, either directly through its sales subsidiaries, or through third-party distributors.

Contact

BASEL-STADT
Basel
Hochbergerstrasse 60E
+41616333434.0
www.medartis.com

IPO

2018-03-23

Employees

684

Officers

CEO & Member of Executive Management Board
Dr. Christoph Bronnimann
Founder & Vice Chairman
Dr. Thomas Straumann
CFO & Member of the Executive Management Board
Dr. Dirk W. Kirsten
VP of EMEA & Member of Executive Management Board
Ms. Mareike Loch
CTO & Member of the Executive Board
Mr. Manuel Schaer
COO & Member of Management Board
Mr. Mario Della Casa
Show More
Chief Human Resources Officer & Executive Management Board Member
Ms. Inge Maes
Head of Regulatory Affairs
Ms. Anisha Wharton
Show Less

See Also

Discover More
What is the Intrinsic Value of one MED stock?

The intrinsic value of one MED stock under the Base Case scenario is 87.83 CHF.

Is MED stock undervalued or overvalued?

Compared to the current market price of 52 CHF, Medartis Holding AG is Undervalued by 41%.

Back to Top